

10-08-1998

3 SHEET
ONLY

MND 7-15-98

Tab settings → → → ▼

To the Honorable Commissioner



100794251

the attached original documents or copy thereof

1. Name of conveying party(ies):
King Pharmaceuticals, Inc.

Individual(s) Association
 General Partnership Limited Partnership
 Corporation-State
 Other _____

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies):
Name Credit Suisse First Boston
Internal Address _____
Street Address Eleven Madison Avenue
City: New York State: NY ZIP: 10010

Individual(s) citizenship _____
 Association _____
 General Partnership _____
 Limited Partnership _____
 Corporation-State NY
 Other _____

If assignee is not domiciled in the United States, a domestic representative designation is attached. Yes No
 Designations must be a separate document from this document.
 Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance:

Assignment Merge
 Security Agreement Change of Name
 Other _____

Execution Date February 27, 1998

4. Application number(s) or registration number(s)

A. Trademark Application No (s)

B. Trademark registration No (s)

SEE ATTACHED

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Anne Lewallen
Internal Address _____
Street Address: Crawath, Swaine & Moore
Worldwide Plaza, 825 Eighth Avenue
City: New York State: NY ZIP: 10017

6. Total number of applications and registrations involved: 36

7. Total fee (37 CFR 3.411) 915.00

Enclosed

Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

07/17/1998 JSHABAZZ 00000015 2030333

DO NOT USE THIS SPACE

01 FC:481 40.00 DP
02 FC:482 875.00 DP

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

MANAR TABRIZI
Name of Person Signing

Manar Tabrizi
Signature

TRADEMARK 6/16/98
Date

REEL 1759 FRAME: 0663
Total number of pages comprising cover sheet

62

Trademarks

Monarch Pharmaceuticals, Inc.

Registered Trademarks

Vita Care

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 2,030,333
Date of Registration: 1-14-97
Country of Issue: United States of America

Pediotic

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 1,498,288
Date of Registration: 8-2-88
Date of Assignment: 4-15-97
Country of Issue: United States of America

Design Only - the drawing consists of a kidney-shaped tablet

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 1,350,257
Date of Registration: 7-23-85
Date of Assignment: 1-24-97
Country of Issue: United States of America

Thalitone

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 1,216,341
Date of Registration: 11-16-82
Date of Assignment: 1-24-97
Country of Issue: United States of America

Nucofed

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 1,101,912
Date of Registration: 9-12-78
Date of Assignment: 10-11-96
Country of Issue: United States of America

Viroptic

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 1,018,684
Date of Registration: 8-26-75
Date of Assignment: 5-20-97
Country of Issue: United States of America

Cortisporin

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,616,775
Date of Registration: 11-29-55
Date of Assignment: 4-9-97
Country of Issue: United States of America

Tussend

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,830,944
Date of Registration: 6-27-97
Date of Assignment: 10-15-96
Country of Issue: United States of America

Quibron

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,735,573
Date of Registration: 8-7-62
Date of Assignment: 10-11-96
Country of Issue: United States of America

Accudose

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 2,029,430
Date of Registration: 1-14-97
Country of Issue: United States of America

Kemadrin

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,581,264
Date of Registration: 10-20-53
Date of Assignment: Pending
Country of Issue: United States of America

Pro-Kemadrin

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,764,204
Date of Registration: 2-4-64
Date of Assignment: Pending
Country of Issue: United States of America

Mantadil

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 1,621,988
Date of Registration: 11-13-90
Date of Assignment: Pending
Country of Issue: United States of America

Proloprim

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,806,889
Date of Registration: 4-12-66
Date of Assignment: Pending
Country of Issue: United States of America

Septra

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,904,178
Date of Registration: 12-15-70
Date of Assignment: Pending
Country of Issue: United States of America

Proctocort

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 2,132,640
Date of Registration: 1-27-98
Country: United States of America

Pending Trademarks**Virtopic**

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Pending as an Intent to Use Application
Filing Date: 9-8-97
Serial Number: 73/028,216
Country: United States of America

Monarchpharm

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 35 (Advertising and Business Services)
Status: Pending as a New Application
Filing Date: 6-6-97
Serial Number: 75/304,506
Country: United States of America

Monahist

Owner/Applicant: Monarch Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Pending as an Intent to Use Application
Filing Date: 5-22-97
Serial Number: 75/296,273
Country: United States of America

Licensed Registered Trademarks**Neosporin**

Owner: Warner-Lambert Company
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,572,764
Date of Registration: 3-31-53
Date of Licensure: 11-14-97
Country of Issue: United States of America

Polysporin

Owner: Warner-Lambert Company
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,546,132
Date of Registration: 7-31-51
Date of Licensure: 11-14-97
Country of Issue: United States of America

Service Marks

Secure-A-Sample

Owner/Applicant:	Monarch Pharmaceuticals, Inc.
Class(es):	International Class 42 (Miscellaneous Service Marks)
Status:	Registered
Registration Number:	1,983,864
Date of Registration:	7-2-96
Country of Issue:	United States of America

King Pharmaceuticals, Inc.

Registered Trademarks

Monarch Pharmaceuticals

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 2,031,644
Date of Registration: 1-21-97
Country of Issue: United States of America

Monarch Pharmaceuticals and Design

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 2,031,645
Date of Registration: 1-21-97
Country of Issue: United States of America

Royal Vet

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals) &
Class 3 (Cosmetics & Cleaning Preparations)
Status: Registered
Registration Number: 2,029,678
Date of Registration: 1-14-97
Country of Issue: United States of America

Pending Trademarks

Show Winner

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals) &
Class 3 (Cosmetics & Cleaning Preparations)
Status: Pending as an Intent to Use Application
Filing Date: 12/1/96
Serial Number:
Country: United States of America

Petrin

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Pending as an Intent to Use Application
Filing Date: 8-27-97
Serial Number: 75/347,996
Country: United States of America

Arthose Chews

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Pending as an Intent to Use Application
Filing Date: 8-27-97
Serial Number: 75/347,837
Country: United States of America

Vetrin

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals)
Status: Pending as an Intent to Use Application
Filing Date: 8-27-97
Serial Number: 75/347,765
Country: United States of America

King Pharmaceuticals

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals) &
Class 10 (Veterinary & Diagnostic Preparations)
Status: Pending as an Intent to Use Application
Filing Date: 7-12-95
Serial Number: 74/700,382
Country: United States of America

King Pharmaceuticals and Design

Owner/Applicant: King Pharmaceuticals, Inc.
Class(es): International Class 5 (Pharmaceuticals) &
Class 10 (Veterinary & Diagnostic Preparations)
Status: Pending as an Intent to Use Application
Filing Date: 7-12-95
Serial Number: 74/700,380
Country: United States of America

UCC-3 Financing Statements

<u>Filing</u>	<u>Filing Office</u>
1. King Pharmaceuticals, Inc. (Debtor) Boehringer Mannheim Pharmaceuticals Corp. (Secured Party)	Sullivan Co., TN
2. King Pharmaceuticals, Inc. (Debtor) First Tennessee Bank National Association (Secured Party)	Tennessee Secretary of State
3. Monarch Pharmaceuticals, Inc. (Debtor) General Electric Capital Corporation, as Agent (Secured Party)	Tennessee Secretary of State
4. Monarch Pharmaceuticals, Inc. (Debtor) General Electric Capital Corporation, as Agent (Secured Party)	Tennessee Secretary of State
5. King Pharmaceuticals of Nevada, Inc. (Debtor) General Electric Capital Corporation, as Agent (Secured Party)	Tennessee Secretary of State
6. King Pharmaceuticals, Inc. (Debtor) General Electric Capital Corporation, as Agent (Secured Party)	Tennessee Secretary of State

FilingFiling Office

TRADEMARK

REEL: 1759 FRAME: 0672

<u>Filing</u>	<u>Filing Office</u>
7. King Pharmaceuticals, Inc. (Debtor)	Sullivan Co., TN
First American National Bank (Secured Party)	
8. King Pharmaceuticals, Inc. (Debtor)	Sullivan Co., TN
First American National Bank (Secured Party)	
9. King Pharmaceuticals, Inc. (Debtor)	Sullivan Co., TN
First Tennessee Bank National Association (Secured Party)	

SECURITY AGREEMENT dated as of February 27, 1998, among KING PHARMACEUTICALS, INC., a Tennessee corporation (the "*Borrower*"), each subsidiary of the Borrower listed on Schedule I hereto (each such subsidiary individually a "*Guarantor*" and collectively, the "*Guarantors*"; the Guarantors and the Borrower are referred to collectively herein as the "*Grantors*") and CREDIT SUISSE FIRST BOSTON, a bank organized under the laws of Switzerland, acting through its New York Branch ("*CSFB*"), as collateral agent (in such capacity, the "*Collateral Agent*") for the Secured Parties (as defined herein).

Reference is made to (a) the Credit Agreement dated as of February 27, 1998 (as amended, supplemented or otherwise modified from time to time, the "*Credit Agreement*"), among the Borrower, the lenders from time to time party thereto (the "*Lenders*"), CSFB, as administrative agent (in such capacity, the "*Administrative Agent*"), Collateral Agent and swingline lender, and Wachovia Bank, N.A., as issuing bank (in such capacity, the "*Issuing Bank*"), and (b) the Guarantee Agreement dated as of February 27, 1998 (as amended, supplemented or otherwise modified from time to time, the "*Guarantee Agreement*"), among the Guarantors and the Collateral Agent.

The Lenders have agreed to make Loans to the Borrower, and the Issuing Bank has agreed to issue Letters of Credit for the account of the Borrower, pursuant to, upon the terms and subject to the conditions specified in the Credit Agreement. Each of the Guarantors has agreed to guarantee, among other things, all the obligations of the Borrower under the Credit Agreement. The obligations of the Lenders to make Loans and of the Issuing Bank to issue Letters of Credit are conditioned upon, among other things, the execution and delivery by the Grantors of an agreement in the form hereof to secure (a) the due and punctual payment by the Borrower of (i) the principal of, premium, if any, and interest (including interest accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding) on the Loans, when and as due, whether at maturity, by acceleration, upon one or more dates set for prepayment or otherwise, (ii) each payment required to be made by the Borrower under the Credit Agreement in respect of any Letter of Credit, when and as due, including payments in respect of reimbursement of disbursements, interest thereon and obligations to provide cash collateral and (iii) all other monetary obligations, including fees, costs, expenses and indemnities, whether primary, secondary, direct, contingent, fixed or otherwise (including monetary obligations incurred during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding), of the Loan Parties to the Secured Parties under the Credit Agreement and the other Loan Documents, (b) the due and punctual payment and performance of all the covenants, agreements, obligations and liabilities of each Loan Party under or pursuant to this Agreement and the other Loan Documents and (c) the due and punctual payment and performance of all obligations of the Borrower under each Hedging Agreement entered into with any counterparty that was a Lender at the time such Hedging Agreement was entered into (all the monetary and other obligations described in the preceding clauses (a) through (c) being collectively called the "*Obligations*").

“*Documents*” shall mean all instruments, certificates representing shares of capital securities, files, records, ledger sheets and documents covering or relating to any of the Collateral.

“*Equipment*” shall mean all equipment, furniture and furnishings and all tangible personal property similar to any of the foregoing, including tools, parts and supplies of every kind and description, and all improvements, accessions or appurtenances thereto, that are now or hereafter owned by any Grantor. The term Equipment shall include Fixtures

“*Fixtures*” shall mean all items of Equipment, whether now owned or hereafter acquired, of any Grantor that become so related to particular real estate that an interest in them arises under any real estate law applicable thereto.

“*General Intangibles*” shall mean all choses in action and causes of action and all other assignable intangible personal property of any Grantor of every kind and nature (other than Accounts Receivable) now owned or hereafter acquired by any Grantor, including corporate or other business records, indemnification claims, contract rights (including rights under leases, whether entered into as lessor or lessee, Hedging Agreements and other agreements), goodwill, registrations, franchises, tax refund claims and any letter of credit, guarantee, claim, security interest or other security held by or granted to any Grantor to secure payment by an Account Debtor of any of the Accounts Receivable.

“*Intellectual Property*” shall mean all intangible, intellectual and similar property of any Grantor of every kind and nature now owned or hereafter acquired by any Grantor, including inventions, designs, Patents, Copyrights, Licenses, Trademarks, trade secrets, confidential or proprietary technical and business information, know-how, show-how or other data or information, software and databases and all embodiments or fixations thereof and related documentation, registrations and franchises, and all additions, improvements and accessions to, and books and records describing or used in connection with, any of the foregoing

“*Inventory*” shall mean all goods of any Grantor, whether now owned or hereafter acquired, held for sale or lease, or furnished or to be furnished by any Grantor under contracts of service or consumed in any Grantor's business, including raw materials, intermediates, work in process, packaging materials, finished goods, semi-finished inventory, scrap inventory, manufacturing supplies and spare parts, and all such goods that have been returned to or repossessed by or on behalf of any Grantor.

“*License*” shall mean any Patent License, Trademark License, Copyright License or other license or sublicense to which any Grantor is a party, including those listed on Schedule III (other than those license agreements in existence on the date hereof and listed on Schedule III and those license agreements entered into after the date hereof, which by their terms prohibit assignment or a grant of a security interest by such Grantor as licensee thereunder).

“*Obligations*” shall have the meaning assigned to such term in the preliminary statement of this Agreement

“*Patent License*” shall mean any written agreement, now or hereafter in effect, granting to any third party any right to make, use or sell any invention on which a Patent, now or hereafter owned by any Grantor or which any Grantor otherwise has the right to license.

is in existence, or granting to any Grantor any right to make, use or sell any invention on which a Patent, now or hereafter owned by any third party, is in existence, and all rights of any Grantor under any such agreement.

"Patents" shall mean all of the following now owned or hereafter acquired by any Grantor: (a) all letters patent of the United States or any other country, all registrations and recordings thereof and all applications for letters patent of the United States or any other country, including registrations, recordings and pending applications in the United States Patent and Trademark Office or any similar offices in any other country, including those listed on Schedule IV, and (b) all reissues, continuations, divisions, continuations-in-part, renewals or extensions thereof and the inventions disclosed or claimed therein, including the right to make, use and/or sell the inventions disclosed or claimed therein.

"Perfection Certificate" shall mean a certificate substantially in the form of Annex 1 hereto, completed and supplemented with the schedules and attachments contemplated thereby, and duly executed by a Financial Officer and the chief legal officer of the Borrower.

"Proceeds" shall mean any consideration received from the sale, exchange, license, lease or other disposition of any asset or property that constitutes Collateral, any value received as a consequence of the possession of any Collateral, any payment received from any insurer or other person or entity as a result of the destruction, loss, theft, damage or other involuntary conversion of whatever nature of any asset or property which constitutes Collateral and shall include (a) any claim of any Grantor against any third party for (and the right to sue and recover for and the rights to damages or profits due or accrued arising out of or in connection with) (i) past, present or future infringement of any Patent now or hereafter owned by any Grantor or licensed under a Patent License, (ii) past, present or future infringement or dilution of any Trademark now or hereafter owned by any Grantor or licensed under a Trademark License or injury to the goodwill associated with or symbolized by any Trademark now or hereafter owned by any Grantor, (iii) past, present or future breach of any License and (iv) past, present or future infringement of any Copyright now or hereafter owned by any Grantor or licensed under a Copyright License and (b) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral.

"Secured Parties" shall mean (a) the Lenders, (b) the Administrative Agent, (c) the Collateral Agent, (d) the Issuing Bank, (e) each counterparty to an Hedging Agreement entered into with the Borrower if such counterparty was a Lender at the time the Hedging Agreement was entered into, (f) the beneficiaries of each indemnification obligation undertaken by any Grantor under any Loan Document and (g) the successors and assigns of each of the foregoing.

"Security Interest" shall have the meaning assigned to such term in Section 2.01.

"Trademark License" shall mean any written agreement, now or hereafter in effect, granting to any third party any right to use any Trademark now or hereafter owned by any Grantor or which any Grantor otherwise has the right to license, or granting to any Grantor any right to use any Trademark now or hereafter owned by any third party, and all rights of any Grantor under any such agreement.

"Trademarks" shall mean all of the following now owned or hereafter acquired by any Grantor: (a) all trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, logos, other source or

TRADEMARK

REEL: 1759 FRAME: 0676

business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all registration and recording applications filed in connection therewith, including registrations and registration applications in the United States Patent and Trademark Office, any State of the United States or any similar offices in any other country or any political subdivision thereof, and all extensions or renewals thereof, including those listed on Schedule V, (b) all goodwill associated therewith or symbolized thereby and (c) all other assets, rights and interests that uniquely reflect or embody such goodwill.

SECTION 1.03. *Rules of Interpretation.* The rules of interpretation specified in Section 1.02 of the Credit Agreement shall be applicable to this Agreement.

ARTICLE II

Security Interest

SECTION 2.01. *Security Interest.* As security for the payment or performance, as the case may be, in full of the Obligations, each Grantor hereby bargains, sells, conveys, assigns, sets over, mortgages, pledges, hypothecates and transfers to the Collateral Agent, its successors and assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and assigns, for the ratable benefit of the Secured Parties, a security interest in, all of such Grantor's right, title and interest in, to and under the Collateral (the "*Security Interest*"). Without limiting the foregoing, the Collateral Agent is hereby authorized to file one or more financing statements (including fixture filings), continuation statements, filings with the United States Patent and Trademark Office or United States Copyright Office (or any successor office or any similar office in any other country) or other documents for the purpose of perfecting, confirming, continuing, enforcing or protecting the Security Interest granted by each Grantor, without the signature of any Grantor, and naming any Grantor or the Grantors as debtors and the Collateral Agent as secured party.

SECTION 2.02. *No Assumption of Liability.* The Security Interest is granted as security only and shall not subject the Collateral Agent or any other Secured Party to, or in any way alter or modify, any obligation or liability of any Grantor with respect to or arising out of the Collateral.

ARTICLE III

Representations and Warranties

The Grantors jointly and severally represent and warrant to the Collateral Agent and the Secured Parties that:

SECTION 3.01. *Title and Authority.* Each Grantor has good and valid rights in and title to the Collateral with respect to which it has purported to grant a Security Interest hereunder and has full power and authority to grant to the Collateral Agent the Security Interest in such Collateral pursuant hereto and to execute, deliver and perform its obligations in accordance with the terms of this Agreement, without the consent or approval of any other person other than any consent or approval which has been obtained

SECTION 3.02. *Filings* (a) The Perfection Certificate has been duly prepared, completed and executed and the information set forth therein is correct and complete. Fully executed Uniform Commercial Code financing statements (including fixture filings, as applicable) or other appropriate filings, recordings or registrations containing a description of the Collateral have been delivered to the Collateral Agent for filing in each governmental, municipal or other office specified in Schedule 6 to the Perfection Certificate, which are all the filings, recordings and registrations (other than filings required to be made in the United States Patent and Trademark Office and the United States Copyright Office in order to perfect the Security Interest in Collateral consisting of United States Patents, Trademarks and Copyrights) that are necessary to publish notice of and protect the validity of and to establish a legal, valid and perfected security interest in favor of the Collateral Agent (for the ratable benefit of the Secured Parties) in respect of all Collateral in which the Security Interest may be perfected by filing, recording or registration in the United States (or any political subdivision thereof) and its territories and possessions, and no further or subsequent filing, refiling, recording, rerecording, registration or reregistration is necessary in any such jurisdiction, except as provided under applicable law with respect to the filing of continuation statements.

(b) Each Grantor represents and warrants that fully executed security agreements in the form hereof and containing a description of all Collateral consisting of Intellectual Property shall have been received and recorded within three months after the execution of this Agreement with respect to United States Patents and United States registered Trademarks (and Trademarks for which United States registration applications are pending) and within one month after the execution of this Agreement with respect to United States registered Copyrights by the United States Patent and Trademark Office and the United States Copyright Office pursuant to 35 U.S.C. § 261, 15 U.S.C. § 1060 or 17 U.S.C. § 205 and the regulations thereunder, as applicable, and otherwise as may be required pursuant to the laws of any other necessary jurisdiction, to protect the validity of and to establish a legal, valid and perfected security interest in favor of the Collateral Agent (for the ratable benefit of the Secured Parties) in respect of all Collateral consisting of Patents, Trademarks and Copyrights in which a security interest may be perfected by filing, recording or registration in the United States (or any political subdivision thereof) and its territories and possessions, or in any other necessary jurisdiction, and no further or subsequent filing, refiling, recording, reregistration or reregistration is necessary (other than such actions as are necessary to perfect the Security Interest with respect to any Collateral consisting of Patents, Trademarks and Copyrights (or registration or application for registration thereof) acquired or developed after the date hereof).

SECTION 3.03. *Validity of Security Interest.* The Security Interest constitutes (a) a legal and valid security interest in all the Collateral securing the payment and performance of the Obligations, (b) subject to the filings described in Section 3.02 above, a perfected security interest in all Collateral in which a security interest may be perfected by filing, recording or registering a financing statement or analogous document in the United States (or any political subdivision thereof) and its territories and possessions pursuant to the Uniform Commercial Code or other applicable law in such jurisdictions and (c) a security interest that shall be perfected in all Collateral in which a security interest may be perfected upon the receipt and recording of this Agreement with the United States Patent and Trademark Office and the United States Copyright Office, as applicable, within the three month period (commencing as of the date hereof) pursuant to 35 U.S.C. § 261 or 15 U.S.C. § 1060 or the one month period (commencing as of the date hereof) pursuant to 17 U.S.C. § 205 and otherwise as may be required pursuant to the laws of any other necessary jurisdiction. The

TRADEMARK

REEL: 1759 FRAME: 0678

tion required pursuant to Section 2 of the Perfection Certificate or confirming that there has been no change in such information since the date of such certificate or the date of the most recent certificate delivered pursuant to Section 4.02 and (b) certifying that all Uniform Commercial Code financing statements (including fixture filings, as applicable) or other appropriate filings, recordings or registrations, including all refilings, rerecordings and reregistrations, containing a description of the Collateral have been filed of record in each governmental, municipal or other appropriate office in each jurisdiction identified pursuant to clause (a) above to the extent necessary to protect and perfect the Security Interest for a period of not less than 18 months after the date of such certificate (except as noted therein with respect to any continuation statements to be filed within such period). Each certificate delivered pursuant to this Section 4.02 shall identify in the format of Schedule II, III, IV or V, as applicable, all Intellectual Property of any Grantor in existence on the date thereof and not then listed on such Schedules or previously so identified to the Collateral Agent

SECTION 4.03. *Protection of Security.* Each Grantor shall, at its own cost and expense, take any and all actions necessary to defend title to the Collateral against all persons and to defend the Security Interest of the Collateral Agent in the Collateral and the priority thereof against any Lien not expressly permitted pursuant to Section 6.02 of the Credit Agreement.

SECTION 4.04. *Further Assurances.* Each Grantor agrees, at its own expense, to execute, acknowledge, deliver and cause to be duly filed all such further instruments and documents and take all such actions as the Collateral Agent may from time to time reasonably request to better assure, preserve, protect and perfect the Security Interest and the rights and remedies created hereby, including the payment of any fees and taxes required in connection with the execution and delivery of this Agreement, the granting of the Security Interest and the filing of any financing statements (including fixture filings) or other documents in connection herewith or therewith. If any amount payable under or in connection with any of the Collateral shall be or become evidenced by any promissory note or other instrument, such note or instrument shall be immediately pledged and delivered to the Collateral Agent, duly endorsed in a manner satisfactory to the Collateral Agent.

Without limiting the generality of the foregoing, each Grantor hereby authorizes the Collateral Agent, with prompt notice thereof to the Grantors, to supplement this Agreement by supplementing Schedule II, III, IV or V hereto or adding additional schedules hereto to specifically identify any asset or item that may constitute Copyrights, Licenses, Patents or Trademarks; *provided, however*, that any Grantor shall have the right, exercisable within 10 days after it has been notified by the Collateral Agent of the specific identification of such Collateral, to advise the Collateral Agent in writing of any inaccuracy of the representations and warranties made by such Grantor hereunder with respect to such Collateral. Each Grantor agrees that it will use its best efforts to take such action as shall be necessary in order that all representations and warranties hereunder shall be true and correct with respect to such Collateral within 30 days after the date it has been notified by the Collateral Agent of the specific identification of such Collateral.

SECTION 4.05. *Inspection and Verification.* The Collateral Agent and such persons as the Collateral Agent may reasonably designate shall have the right, at the Grantors' own cost and expense, to inspect the Collateral, all records related thereto (and to make extracts and copies from such records) and the premises upon which any of the Collateral is located, to discuss the Grantors' affairs with the officers of the Grantors and their independent accountants and to verify under reasonable procedures, in accordance with Section 5.10 of the Credit

TRADEMARK

Agreement, the validity, amount, quality, quantity, value, condition and status of, or any other matter relating to, the Collateral, including, in the case of Accounts or Collateral in the possession of any third person, by contacting Account Debtors or the third person possessing such Collateral for the purpose of making such a verification. The Collateral Agent shall have the absolute right to share any information it gains from such inspection or verification with any Secured Party (it being understood that any such information shall be deemed to be "Information" subject to the provisions of Section 9.16).

SECTION 4.06. *Taxes; Encumbrances.* At its option, the Collateral Agent may discharge past due taxes, assessments, charges, fees, Liens, security interests or other encumbrances at any time levied or placed on the Collateral and not permitted pursuant to Section 6.02 of the Credit Agreement, and may pay for the maintenance and preservation of the Collateral to the extent any Grantor fails to do so as required by the Credit Agreement or this Agreement, and each Grantor jointly and severally agrees to reimburse the Collateral Agent on demand for any payment made or any expense incurred by the Collateral Agent pursuant to the foregoing authorization; *provided, however*, that nothing in this Section 4.06 shall be interpreted as excusing any Grantor from the performance of, or imposing any obligation on the Collateral Agent or any Secured Party to cure or perform, any covenants or other promises of any Grantor with respect to taxes, assessments, charges, fees, liens, security interests or other encumbrances and maintenance as set forth herein or in the other Loan Documents.

SECTION 4.07. *Assignment of Security Interest.* If at any time any Grantor shall take a security interest in any property of an Account Debtor or any other person to secure payment and performance of an Account, such Grantor shall promptly assign such security interest to the Collateral Agent. Such assignment need not be filed of public record unless necessary to continue the perfected status of the security interest against creditors of and transferees from the Account Debtor or other person granting the security interest.

SECTION 4.08. *Continuing Obligations of the Grantors.* Each Grantor shall remain liable to observe and perform all the conditions and obligations to be observed and performed by it under each contract, agreement or instrument relating to the Collateral, all in accordance with the terms and conditions thereof, and each Grantor jointly and severally agrees to indemnify and hold harmless the Collateral Agent and the Secured Parties from and against any and all liability for such performance.

SECTION 4.09. *Use and Disposition of Collateral.* None of the Grantors shall make or permit to be made an assignment, pledge or hypothecation of the Collateral or shall grant any other Lien in respect of the Collateral, except as expressly permitted by Section 6.02 of the Credit Agreement. None of the Grantors shall make or permit to be made any transfer of the Collateral and each Grantor shall remain at all times in possession of the Collateral owned by it, except that (a) Inventory may be sold in the ordinary course of business and (b) unless and until the Collateral Agent shall notify the Grantors that an Event of Default shall have occurred and be continuing and that during the continuance thereof the Grantors shall not sell, convey, lease, assign, transfer or otherwise dispose of any Collateral (which notice may be given by telephone if promptly confirmed in writing), the Grantors may use and dispose of the Collateral in any lawful manner not inconsistent with the provisions of this Agreement, the Credit Agreement or any other Loan Document. Without limiting the generality of the foregoing, each Grantor agrees that it shall not permit any Inventory to be in the possession or control of any warehouseman, bailee, agent or processor at any time unless such warehouseman, bailee, agent or processor shall have been notified of the Security

TRADEMARK

REEL: 1759 FRAME: 0681

Interest and shall have agreed in writing to hold the Inventory subject to the Security Interest and the instructions of the Collateral Agent and to waive and release any Lien held by it with respect to such Inventory, whether arising by operation of law or otherwise.

SECTION 4.10. *Limitation on Modification of Accounts.* None of the Grantors will, without the Collateral Agent's prior written consent, grant any extension of the time of payment of any of the Accounts Receivable, compromise, compound or settle the same for less than the full amount thereof, release, wholly or partly, any person liable for the payment thereof or allow any credit or discount whatsoever thereon, other than extensions, credits, discounts, compromises or settlements granted or made in the ordinary course of business and consistent with its current practices and in accordance with such prudent and standard practices used in industries that are the same as or similar to those in which such Grantor is engaged.

SECTION 4.11. *Insurance.* The Grantors, at their own expense, shall keep or cause to be kept the Inventory and Equipment adequately insured at all times by financially sound and reputable insurers; maintain such other insurance, to such extent and against such risks, including fire and other risks insured against by extended coverage, as is customary with companies in the same or similar businesses operating in the same or similar locations, including public liability insurance against claims for personal injury or death or property damage occurring upon, in, about or in connection with the use of any properties owned, occupied or controlled by it; and maintain such other insurance as may be required by law.

(b) The Grantor shall: (i) cause all such policies to be endorsed or otherwise amended to include a "standard" or "New York" lender's loss payable endorsement, in form and substance satisfactory to the Administrative Agent and the Collateral Agent, which endorsement shall provide that, from and after the Closing Date, if the insurance carrier shall have received written notice from the Administrative Agent or the Collateral Agent of the occurrence of an Event of Default, the insurance carrier shall pay all proceeds otherwise payable to the Borrower or the Loan Parties under such policies directly to the Collateral Agent; (ii) deliver original or certified copies of all such policies to the Collateral Agent; (iii) cause each such policy to provide that it shall not be canceled, modified or not renewed (x) by reason of nonpayment of premium upon not less than 10 days' prior written notice thereof by the insurer to the Administrative Agent and the Collateral Agent (giving the Administrative Agent and the Collateral Agent the right to cure defaults in the payment of premiums) or (y) for any other reason upon not less than 30 days' prior written notice thereof by the insurer to the Administrative Agent and the Collateral Agent; and (iv) deliver to the Administrative Agent and the Collateral Agent, prior to the cancellation, modification or nonrenewal of any such policy of insurance, a copy of a renewal or replacement policy (or other evidence of renewal of a policy previously delivered to the Administrative Agent and the Collateral Agent) together with evidence satisfactory to the Administrative Agent and the Collateral Agent of payment of the premium therefor.

(c) The Mortgagor shall notify the Administrative Agent and the Collateral Agent immediately whenever any separate insurance concurrent in form or contributing in the event of loss with that required to be maintained under this Section 4.11 is taken out by the Borrower; and promptly deliver to the Administrative Agent and the Collateral Agent a duplicate original copy of such policy or policies.

(d) In connection with the covenants set forth in this Section 4.11, it is understood and agreed that:

(i) none of the Administrative Agent, the Lenders, the Issuing Bank, or their respective agents or employees shall be liable for any loss or damage insured by the insurance policies required to be maintained under this Section 4.11, it being understood that (A) the Borrower and the other Loan Parties shall look solely to their insurance companies or any other parties other than the aforesaid parties for the recovery of such loss or damage and (B) such insurance companies shall have no rights of subrogation against the Administrative Agent, the Collateral Agent, the Lenders, the Issuing Bank or their agents or employees. If, however, the insurance policies do not provide waiver of subrogation rights against such parties, as required above, then the Borrower hereby agrees, to the extent permitted by law, to waive its right of recovery, if any, against the Administrative Agent, the Collateral Agent, the Lenders, the Issuing Bank and their agents and employees; and

(ii) the designation of any form, type or amount of insurance coverage by the Administrative Agent, the Collateral Agent or the Required Lenders under this Section 4.11 shall in no event be deemed a representation, warranty or advice by the Administrative Agent, the Collateral Agent or the Lenders that such insurance is adequate for the purposes of the business of the Borrower and the Subsidiaries or the protection of their properties and the Administrative Agent, the Collateral Agent and the Required Lenders shall have the right from time to time to require the Borrower and the other Loan Parties to keep other insurance in such form and amount as the Administrative Agent, the Collateral Agent or the Required Lenders may reasonably request, provided that such insurance shall be obtainable on commercially reasonable terms.

(e) Each Grantor irrevocably makes, constitutes and appoints the Collateral Agent (and all officers, employees or agents designated by the Collateral Agent) as such Grantor's true and lawful agent (and attorney-in-fact) for the purpose, during the continuance of an Event of Default, of making, settling and adjusting claims in respect of Collateral under policies of insurance, endorsing the name of such Grantor on any check, draft, instrument or other item of payment for the proceeds of such policies of insurance and for making all determinations and decisions with respect thereto. In the event that any Grantor at any time or times shall fail to obtain or maintain any of the policies of insurance required hereby or to pay any premium in whole or part relating thereto, the Collateral Agent may, without waiving or releasing any obligation or liability of the Grantors hereunder or any Event of Default, in its sole discretion, obtain and maintain such policies of insurance and pay such premium and take any other actions with respect thereto as the Collateral Agent deems advisable. All sums disbursed by the Collateral Agent in connection with this Section 4.11, including reasonable attorneys' fees, court costs, expenses and other charges relating thereto, shall be payable, upon demand, by the Grantors to the Collateral Agent and shall be additional Obligations secured hereby

SECTION 4.12 *Legend* Each Grantor shall legend, in form and manner satisfactory to the Collateral Agent, its Accounts Receivable and its books, records and documents evidencing or pertaining thereto with an appropriate reference to the fact that such Accounts Receivable have been assigned to the Collateral Agent for the benefit of the Secured Parties and that the Collateral Agent has a security interest therein

SECTION 4.13. *Covenants Regarding Patent, Trademark and Copyright Collateral.*

(a) Each Grantor agrees that it will not, nor will it permit any of its licensees to, do any act, or omit to do any act, whereby any Patent which is material to the conduct of such Grantor's business may become invalidated or dedicated to the public, and agrees that it shall continue to mark any products covered by a Patent with the relevant patent number as necessary and sufficient to establish and preserve its maximum rights under applicable patent laws.

(b) Each Grantor (either itself or through its licensees or its sublicensees) will, for each Trademark material to the conduct of such Grantor's business, (i) maintain such Trademark in full force free from any claim of abandonment or invalidity for non-use, (ii) maintain the quality of products and services offered under such Trademark, (iii) display such Trademark with notice of Federal or foreign registration to the extent necessary and sufficient to establish and preserve its maximum rights under applicable law and (iv) not knowingly use or knowingly permit the use of such Trademark in violation of any third party rights.

(c) Each Grantor (either itself or through licensees) will, for each work covered by a material Copyright, continue to publish, reproduce, display, adopt and distribute the work with appropriate copyright notice as necessary and sufficient to establish and preserve its maximum rights under applicable copyright laws.

(d) Each Grantor shall notify the Collateral Agent immediately if it knows or has reason to know that any Patent, Trademark or Copyright material to the conduct of its business may become abandoned, lost or dedicated to the public, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, United States Copyright Office or any court or similar office of any country) regarding such Grantor's ownership of any Patent, Trademark or Copyright, its right to register the same, or to keep and maintain the same.

(e) In no event shall any Grantor, either itself or through any agent, employee, licensee or designee, file an application for any Patent, Trademark or Copyright (or for the registration of any Trademark or Copyright) with the United States Patent and Trademark Office, United States Copyright Office or any office or agency in any political subdivision of the United States or in any other country or any political subdivision thereof, unless it promptly informs the Collateral Agent, and, upon request of the Collateral Agent, executes and delivers any and all agreements, instruments, documents and papers as the Collateral Agent may request to evidence the Collateral Agent's security interest in such Patent, Trademark or Copyright, and each Grantor hereby appoints the Collateral Agent as its attorney-in-fact to execute and file such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed; such power, being coupled with an interest, is irrevocable.

(f) Each Grantor will take all necessary steps that are consistent with the practice in any proceeding before the United States Patent and Trademark Office, United States Copyright Office or any office or agency in any political subdivision of the United States or in any other country or any political subdivision thereof, to maintain and pursue each material application relating to the Patents, Trademarks and/or Copyrights (and to obtain the relevant grant or registration) and to maintain each issued Patent and each registration of the Trademarks and Copyrights that is material to the conduct of any Grantor's business, including timely filings of applications for renewal, affidavits of use, affidavits of

incontestability and payment of maintenance fees, and, if consistent with good business judgment, to initiate opposition, interference and cancelation proceedings against third parties.

(g) In the event that any Grantor has reason to believe that any Collateral consisting of a Patent, Trademark or Copyright material to the conduct of any Grantor's business has been or is about to be infringed, misappropriated or diluted by a third party, such Grantor promptly shall notify the Collateral Agent and shall, if consistent with good business judgment, promptly sue for infringement, misappropriation or dilution and to recover any and all damages for such infringement, misappropriation or dilution, and take such other actions as are appropriate under the circumstances to protect such Collateral

(h) Upon and during the continuance of an Event of Default, each Grantor shall use its best efforts to obtain all requisite consents or approvals by the licensor of each Copyright License, Patent License or Trademark License to effect the assignment of all of such Grantor's right, title and interest thereunder to the Collateral Agent or its designee.

ARTICLE V

Power of Attorney

Each Grantor irrevocably makes, constitutes and appoints the Collateral Agent (and all officers, employees or agents designated by the Collateral Agent) as such Grantor's true and lawful agent and attorney-in-fact, and in such capacity the Collateral Agent shall have the right, with power of substitution for each Grantor and in each Grantor's name or otherwise, for the use and benefit of the Collateral Agent and the Secured Parties, upon the occurrence and during the continuance of an Event of Default (a) to receive, endorse, assign and/or deliver any and all notes, acceptances, checks, drafts, money orders or other evidences of payment relating to the Collateral or any part thereof; (b) to demand, collect, receive payment of, give receipt for and give discharges and releases of all or any of the Collateral; (c) to sign the name of any Grantor on any invoice or bill of lading relating to any of the Collateral; (d) to send verifications of Accounts Receivable to any Account Debtor; (e) to commence and prosecute any and all suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect or otherwise realize on all or any of the Collateral or to enforce any rights in respect of any Collateral; (f) to settle, compromise, compound, adjust or defend any actions, suits or proceedings relating to all or any of the Collateral; (g) to notify, or to require any Grantor to notify, Account Debtors to make payment directly to the Collateral Agent; and (h) to use, sell, assign, transfer, pledge, make any agreement with respect to or otherwise deal with all or any of the Collateral, and to do all other acts and things necessary to carry out the purposes of this Agreement, as fully and completely as though the Collateral Agent were the absolute owner of the Collateral for all purposes; *provided, however*, that nothing herein contained shall be construed as requiring or obligating the Collateral Agent or any Secured Party to make any commitment or to make any inquiry as to the nature or sufficiency of any payment received by the Collateral Agent or any Secured Party, or to present or file any claim or notice, or to take any action with respect to the Collateral or any part thereof or the moneys due or to become due in respect thereof or any property covered thereby, and no action taken or omitted to be taken by the Collateral Agent or any Secured Party with respect to the Collateral or any part thereof shall give rise to any defense, counterclaim or offset in favor of any Grantor or to any claim or action against the Collateral Agent or any Secured Party. It is understood and agreed that the appointment of the Collateral Agent as the agent and attorney-in-fact of the Grantors for the purposes set

TRADEMARK

REEL: 1759 FRAME: 0685

forth above is coupled with an interest and is irrevocable. The provisions of this Section shall in no event relieve any Grantor of any of its obligations hereunder or under any other Loan Document with respect to the Collateral or any part thereof or impose any obligation on the Collateral Agent or any Secured Party to proceed in any particular manner with respect to the Collateral or any part thereof, or in any way limit the exercise by the Collateral Agent or any Secured Party of any other or further right which it may have on the date of this Agreement or hereafter, whether hereunder, under any other Loan Document, by law or otherwise.

ARTICLE VI

Remedies

SECTION 6.01. *Remedies upon Default.* Upon the occurrence and during the continuance of an Event of Default, each Grantor agrees to deliver each item of Collateral to the Collateral Agent on demand, and it is agreed that the Collateral Agent shall have the right to take any of or all the following actions at the same or different times: (a) with respect to any Collateral consisting of Intellectual Property, on demand, to cause the Security Interest to become an assignment, transfer and conveyance of any of or all such Collateral by the applicable Grantors to the Collateral Agent or to license or sublicense, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any such Collateral throughout the world on such terms and conditions and in such manner as the Collateral Agent shall determine (other than in violation of any then-existing licensing arrangements to the extent that waivers cannot be obtained), and (b) with or without legal process and with or without prior notice or demand for performance, to take possession of the Collateral and without liability for trespass to enter any premises where the Collateral may be located for the purpose of taking possession of or removing the Collateral and, generally, to exercise any and all rights afforded to a secured party under the Uniform Commercial Code or other applicable law. Without limiting the generality of the foregoing, each Grantor agrees that the Collateral Agent shall have the right, subject to the mandatory requirements of applicable law, to sell or otherwise dispose of all or any part of the Collateral, at public or private sale or at any broker's board or on any securities exchange, for cash, upon credit or for future delivery as the Collateral Agent shall deem appropriate. The Collateral Agent shall be authorized at any such sale (if it deems it advisable to do so) to restrict the prospective bidders or purchasers to persons who will represent and agree that they are purchasing the Collateral for their own account for investment and not with a view to the distribution or sale thereof, and upon consummation of any such sale the Collateral Agent shall have the right to assign, transfer and deliver to the purchaser or purchasers thereof the Collateral so sold. Each such purchaser at any such sale shall hold the property sold absolutely, free from any claim or right on the part of any Grantor, and each Grantor hereby waives (to the extent permitted by law) all rights of redemption, stay and appraisal which such Grantor now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted.

The Collateral Agent shall give the Grantors 10 days' written notice (which each Grantor agrees is reasonable notice within the meaning of Section 9-504(3) of the Uniform Commercial Code as in effect in the State of New York or its equivalent in other jurisdictions) of the Collateral Agent's intention to make any sale of Collateral. Such notice, in the case of a public sale, shall state the time and place for such sale and, in the case of a sale at a broker's board or on a securities exchange, shall state the board or exchange at which such sale is to be made and the day on which the Collateral, or portion thereof, will first be offered for sale at such board or exchange. Any such public sale shall be held at such time or times within

TRADEMARK

REEL: 1759 FRAME: 0686

ordinary business hours and at such place or places as the Collateral Agent may fix and state in the notice (if any) of such sale. At any such sale, the Collateral, or portion thereof, to be sold may be sold in one lot as an entirety or in separate parcels, as the Collateral Agent may (in its sole and absolute discretion) determine. The Collateral Agent shall not be obligated to make any sale of any Collateral if it shall determine not to do so, regardless of the fact that notice of sale of such Collateral shall have been given. The Collateral Agent may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice, be made at the time and place to which the same was so adjourned. In case any sale of all or any part of the Collateral is made on credit or for future delivery, the Collateral so sold may be retained by the Collateral Agent until the sale price is paid by the purchaser or purchasers thereof, but the Collateral Agent shall not incur any liability in case any such purchaser or purchasers shall fail to take up and pay for the Collateral so sold and, in case of any such failure, such Collateral may be sold again upon like notice. At any public (or, to the extent permitted by law, private) sale made pursuant to this Section, any Secured Party may bid for or purchase, free (to the extent permitted by law) from any right of redemption, stay, valuation or appraisal on the part of any Grantor (all said rights being also hereby waived and released to the extent permitted by law), the Collateral or any part thereof offered for sale and may make payment on account thereof by using any claim then due and payable to such Secured Party from any Grantor as a credit against the purchase price, and such Secured Party may, upon compliance with the terms of sale, hold, retain and dispose of such property without further accountability to any Grantor therefor. For purposes hereof, a written agreement to purchase the Collateral or any portion thereof shall be treated as a sale thereof, the Collateral Agent shall be free to carry out such sale pursuant to such agreement and no Grantor shall be entitled to the return of the Collateral or any portion thereof subject thereto, notwithstanding the fact that after the Collateral Agent shall have entered into such an agreement all Events of Default shall have been remedied and the Obligations paid in full. As an alternative to exercising the power of sale herein conferred upon it, the Collateral Agent may proceed by a suit or suits at law or in equity to foreclose this Agreement and to sell the Collateral or any portion thereof pursuant to a judgment or decree of a court or courts having competent jurisdiction or pursuant to a proceeding by a court-appointed receiver

SECTION 6.02. *Application of Proceeds.* The Collateral Agent shall apply the proceeds of any collection or sale of the Collateral, as well as any Collateral consisting of cash, as follows:

FIRST, to the payment of all costs and expenses incurred by the Administrative Agent or the Collateral Agent (in its capacity as such hereunder or under any other Loan Document) in connection with such collection or sale or otherwise in connection with this Agreement or any of the Obligations, including all court costs and the fees and expenses of its agents and legal counsel, the repayment of all advances made by the Collateral Agent hereunder or under any other Loan Document on behalf of any Grantor and any other costs or expenses incurred in connection with the exercise of any right or remedy hereunder or under any other Loan Document;

SECOND, to the payment in full of the Obligations (the amounts so applied to be distributed among the Secured Parties pro rata in accordance with the amounts of the Obligations owed to them on the date of any such distribution); and

TRADEMARK

THIRD, to the Grantors, their successors or assigns, or as a court of competent jurisdiction may otherwise direct.

The Collateral Agent shall have absolute discretion as to the time of application of any such proceeds, moneys or balances in accordance with this Agreement. Upon any sale of the Collateral by the Collateral Agent (including pursuant to a power of sale granted by statute or under a judicial proceeding), the receipt of the Collateral Agent or of the officer making the sale shall be a sufficient discharge to the purchaser or purchasers of the Collateral so sold and such purchaser or purchasers shall not be obligated to see to the application of any part of the purchase money paid over to the Collateral Agent or such officer or be answerable in any way for the misapplication thereof.

SECTION 6.03 *Grant of License to Use Intellectual Property.* For the purpose of enabling the Collateral Agent to exercise rights and remedies under this Article at such time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies, each Grantor hereby grants to the Collateral Agent an irrevocable, non-exclusive license (exercisable without payment of royalty or other compensation to the Grantors) to use, license or sub-license any of the Collateral consisting of Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof. The use of such license by the Collateral Agent shall be exercised, at the option of the Collateral Agent, upon the occurrence and during the continuation of an Event of Default, *provided* that any license, sub-license or other transaction entered into by the Collateral Agent in accordance herewith shall be binding upon the Grantors notwithstanding any subsequent cure of an Event of Default.

ARTICLE VII

Miscellaneous

SECTION 7.01. *Notices.* All communications and notices hereunder shall (except as otherwise expressly permitted herein) be in writing and given as provided in Section 9.01 of the Credit Agreement. All communications and notices hereunder to any Guarantor shall be given to it at its address or telecopy number set forth on Schedule I, with a copy to the Borrower.

SECTION 7.02. *Security Interest Absolute.* All rights of the Collateral Agent hereunder, the Security Interest and all obligations of the Grantors hereunder shall be absolute and unconditional irrespective of (a) any lack of validity or enforceability of the Credit Agreement, any other Loan Document, any agreement with respect to any of the Obligations or any other agreement or instrument relating to any of the foregoing, (b) any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to any departure from the Credit Agreement, any other Loan Document or any other agreement or instrument, (c) any exchange, release or non-perfection of any Lien on other collateral, or any release or amendment or waiver of or consent under or departure from any guarantee, securing or guaranteeing all or any of the Obligations, or (d) any other circumstance that might otherwise constitute a defense available to, or a discharge of, any Grantor in respect of the Obligations or this Agreement.

TRADEMARK

REEL: 1759 FRAME: 0688

SECTION 7.03. *Survival of Agreement.* All covenants, agreements, representations and warranties made by any Grantor herein and in the certificates or other instruments prepared or delivered in connection with or pursuant to this Agreement shall be considered to have been relied upon by the Secured Parties and shall survive the making by the Lenders of the Loans, and the execution and delivery to the Lenders of any notes evidencing such Loans, regardless of any investigation made by the Lenders or on their behalf, and shall continue in full force and effect until this Agreement shall terminate.

SECTION 7.04. *Binding Effect; Several Agreement.* This Agreement shall become effective as to any Grantor when a counterpart hereof executed on behalf of such Grantor shall have been delivered to the Collateral Agent and a counterpart hereof shall have been executed on behalf of the Collateral Agent, and thereafter this Agreement shall be binding upon such Grantor and the Collateral Agent and their respective successors and assigns and shall inure to the benefit of such Grantor, the Collateral Agent and the other Secured Parties and their respective successors and assigns, except that no Grantor shall have the right to assign or transfer its rights or obligations hereunder or any interest herein or in the Collateral (and any such assignment or transfer shall be void) except as expressly contemplated by this Agreement or the Credit Agreement. This Agreement shall be construed as a separate agreement with respect to each Grantor and may be amended, modified, supplemented, waived or released with respect to any Grantor without the approval of any other Grantor and without affecting the obligations of any other Grantor hereunder.

SECTION 7.05. *Successors and Assigns.* Whenever in this Agreement any of the parties hereto is referred to, such reference shall be deemed to include the successors and assigns of such party, and all covenants, promises and agreements by or on behalf of any Grantor or the Collateral Agent that are contained in this Agreement shall bind and inure to the benefit of their respective successors and assigns.

SECTION 7.06. *Collateral Agent's Fees and Expenses; Indemnification.* (a) Each Grantor jointly and severally agrees to pay upon demand to the Collateral Agent the amount of any and all reasonable expenses, including the reasonable fees, disbursements and other charges of its counsel and of any experts or agents, which the Collateral Agent may incur in connection with (i) the administration of this Agreement (including the customary fees and charges of the Collateral Agent for any audits conducted by it or on its behalf with respect to the Accounts Receivable or Inventory), (ii) the custody or preservation of, or the sale of, collection from or other realization upon any of the Collateral, (iii) the exercise, enforcement or protection of any of the rights of the Collateral Agent hereunder or (iv) the failure of any Grantor to perform or observe any of the provisions hereof.

(b) Without limitation of its indemnification obligations under the other Loan Documents, each Grantor jointly and severally agrees to indemnify the Collateral Agent and the other Indemnitees against, and hold each of them harmless from, any and all losses, claims, damages, liabilities and related expenses, including reasonable fees, disbursements and other charges of counsel, incurred by or asserted against any of them arising out of, in any way connected with, or as a result of, the execution, delivery or performance of this Agreement or any claim, litigation, investigation or proceeding relating hereto or to the Collateral, whether or not any Indemnitee is a party thereto; *provided* that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee.

TRADEMARK

REEL: 1759 FRAME: 0689

any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 7.11. *Counterparts.* This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract (subject to Section 7.04), and shall become effective as provided in Section 7.04. Delivery of an executed signature page to this Agreement by facsimile transmission shall be effective as delivery of a manually executed counterpart hereof.

SECTION 7.12. *Headings.* Article and Section headings used herein are for the purpose of reference only, are not part of this Agreement and are not to affect the construction of, or to be taken into consideration in interpreting, this Agreement.

SECTION 7.13. *Jurisdiction; Consent to Service of Process.* (a) Each Grantor hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or the other Loan Documents, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that the Collateral Agent, the Administrative Agent, the Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or the other Loan Documents against any Grantor or its properties in the courts of any jurisdiction.

(b) Each Grantor hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or the other Loan Documents in any New York State or Federal court. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

(c) Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 7.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by law.

SECTION 7.14. *Termination.* This Agreement and the Security Interest shall terminate when all the Obligations have been indefeasibly paid in full, the Lenders have no further commitment to lend, the L/C Exposure has been reduced to zero and the Issuing Bank has no further commitment to issue Letters of Credit under the Credit Agreement, at which time the Collateral Agent shall execute and deliver to the Grantors, at the Grantors' expense, all Uniform Commercial Code termination statements and similar documents which the Grantors shall reasonably request to evidence such termination. Any execution and delivery of termination statements or documents pursuant to this Section 7.14 shall be without

TRADEMARK

REEL: 1759 FRAME: 0691

SECTION 7.15. *Additional Grantors.* Pursuant to Section 5.11 of the Credit Agreement, each Domestic Subsidiary of the Borrower that was not in existence on the date of the Credit Agreement is required to enter into the Security Agreement as a Grantor upon becoming such a Subsidiary. Upon execution and delivery by the Collateral Agent and such a Subsidiary of an instrument in the form of Annex 2 hereto, such Subsidiary shall become a Grantor hereunder with the same force and effect as if originally named as a Grantor herein. The execution and delivery of any such instrument shall not require the consent of any Grantor hereunder. The rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding the addition of any new Grantor as a party to this Agreement.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

KING PHARMACEUTICALS, INC.,

by


 Name:
 Title:

MONARCH PHARMACEUTICALS, INC.,

by


 Name:
 Title:

KING PHARMACEUTICALS OF NEVADA,
 INC.,

by


 Name:
 Title:


PARKEDALE PHARMACEUTICALS, INC.,

by



 Name:
 Title:

TRADEMARK
 REEL: 1759 FRAME: 0693

CREDIT SUISSE FIRST BOSTON, as
Collateral Agent,

by 

Name:
Title:

by 

Name:
Title:

Robert B. Potter
Vice President

Guarantors

Monarch Pharmaceuticals, Inc., a Tennessee Corporation

King Pharmaceuticals of Nevada, Inc., a Nevada Corporation

Parkedale Pharmaceuticals, Inc., a Michigan Corporation

Schedule II to the
Security Agreement

Copyrights

None

Licenses

Licenses assigned to and assumed by Subsidiary, Monarch Pharmaceuticals, Inc. ("Monarch"), from Glaxo Wellcome Inc. ("Glaxo") pursuant to and Assignment and Assumption Agreement dated November 14, 1997, whereby Glaxo assigned to Monarch all of Glaxo's right, title, and interest in the United States, its territories and possessions, under the Trademark, Patent, Copyright, and Know-How License Agreement dated June 30, 1996, between Glaxo and Warner-Lambert Company in and to trademarks as follows:

Neosporin

Owner: Warner-Lambert Company
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,572,764
Date of Registration: 3-31-53
Date of Licensure: 11-14-97
Country of Issue: United States of America

Polysporin

Owner: Warner-Lambert Company
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 0,546,132
Date of Registration: 7-31-51
Date of Licensure: 11-14-97
Country of Issue: United States of America

License granted to Borrower (and/or its Subsidiary, Parkedale Pharmaceuticals, Inc.) pursuant to the License Agreement dated February 27, 1998 between Sellers and Borrower (and/or its Subsidiary, Parkedale Pharmaceuticals, Inc.) as part of the Acquisition providing for the right to use in the United States of America, excluding Puerto Rico, trademarks as follows:

Anusol HC

Owner: Warner-Lambert Company
Class(es): International Class 5 (Pharmaceuticals)
Status: Registered
Registration Number: 811621
Date of Licensure: 2-27-98
Country of Issue: United States of America

Steri-Dose

Owner: Warner-Lambert Company
Status: Registered
Registration Number: 986792
Date of Licensure: 2-27-98
Country of Issue: United States of America

Steri-Vial

Owner: Parke, Davis & Company
Status: Registered
Registration Number: 375423
Date of Licensure: 2-27-98
Country of Issue: United States of America

Steri-Vial

Owner: Parke, Davis & Company
Status: Registered
Registration Number: 549403
Date of Licensure: 2-27-98
Country of Issue: United States of America

Patents

Monarch Pharmaceuticals, Inc.:

U.S. Patent No. 4,933,360 “Novel Chlorthalidone Process and Product”

Issue Date: June 12, 1990

Expiration Date: June 12, 2007

No. of Claims Made: 11

U.S. Patent Nos. 4,465,660; 4,547,358 & 4,215,104

Owner/Applicant: Bristol-Myers Squibb

Status: Registered

Monarch has a paid-up and non-exclusive license to certain patent rights owned or controlled by Bristol-Myers Squibb under the name Dividose and having the patent numbers listed above.

Parkedale Pharmaceuticals, Inc.:

U.S. Patent No. 5,656,296 “Dual Control Sustained Release Drug Delivery Systems and Methods for Preparing Same”

Parkedale Pharmaceuticals, Inc.

Attachment "1" to this Schedule V sets forth a list of Trademarks acquired Parkedale Pharmaceuticals, Inc. from Warner-Lambert Company and Parke, Davis & Company (collectively, the "Sellers") pursuant to the Product Asset Purchase Agreement being entered into between Borrower (and/or its Subsidiary, Parkedale Pharmaceuticals, Inc.) and Sellers, as part of the Acquisition.

The Trademark "Chloromycetin" is subject to the Chloromycetin License Agreement dated February 27, 1998, entered into by and between Sellers and Parkedale Pharmaceuticals, Inc. as part of the Acquisition.

PERFECTION CERTIFICATE

Reference is made to (a) the Credit Agreement dated as of February 27, 1998 (as amended, supplemented or otherwise modified from time to time, the "*Credit Agreement*"), among the Borrower, the lenders from time to time party thereto (the "*Lenders*"), Credit Suisse First Boston, as administrative agent (in such capacity, the "*Administrative Agent*"), Collateral Agent and Swingline Lender, and Wachovia Bank, N.A., as issuing bank (in such capacity, the "*Issuing Bank*"), and (b) Guarantee Agreement dated as of February 27, 1998 (as amended, supplemented or otherwise modified from time to time, the "*Guarantee Agreement*"), among the Guarantors and the Collateral Agent.

The undersigned, a Financial Officer and a Legal Officer, respectively, of the Borrower, hereby certify to the Collateral Agent and each other Secured Party as follows:

1. *Names.* (a) The exact corporate name of each Grantor, as such name appears in its respective certificate of incorporation, is as follows:

King Pharmaceuticals, Inc.

Wholly-owned subsidiaries:

Monarch Pharmaceuticals, Inc.

King Pharmaceuticals of Nevada, Inc.

Parkedale Pharmaceuticals, Inc.

- (b) Set forth below is each other corporate name each Grantor has had in the past five years, together with the date of the relevant change:

**King: RSR Acquisition Corporation - effective September 20, 1993
until January 24, 1994**

**Parkedale: Parkdale Pharmaceuticals, Inc. - effective January 14, 1998
until February 23, 1998**

- (c) Except as set forth in Schedule 1 hereto, no Grantor has changed its identity or corporate structure in any way within the past five years. Changes in identity or corporate structure would include mergers, consolidations and acquisitions, as well as any change in the form, nature or jurisdiction of corporate organization. If any such change has occurred, include in Schedule 1 the information required by Sections 1 and 2 of this certificate as to each acquiree or constituent party to a merger or consolidation.

- (d) The following is a list of all other names (including trade names or similar appellations) used by each Grantor or any of its divisions or other business units in connection with the conduct of its business or the ownership of its properties at any time during the past five years:

**King: Monarch Pharmaceuticals, Royal Vet, Show Winner
King Pharmaceuticals Animal Health**

Monarch: Royal Vet

- (e) Set forth below is the Federal Taxpayer Identification Number of each Grantor:

**King: 54-1684963
Monarch: 62-1643136
Nevada: 88-0348662
Parkedale: 38-3389975**

- 2 *Current Locations.* (a) The chief executive office of each Grantor is located at the address set forth opposite its name below:

<u>Grantor</u>	<u>Mailing Address</u>	<u>County</u>	<u>State</u>
King	501 Fifth Street, Bristol	Sullivan	TN 37620
Monarch	355 Beecham Street, Bristol	Sullivan	TN 37620
Nevada	3753 Howard Hughes Parkway Suite 200, Las Vegas	Clark	NV 89109
Parkedale	500 Woodward, Suite 4000 Detroit (registered office)	Oakland	MI 48226

- (b) Set forth below opposite the name of each Grantor are all locations where such Grantor maintains any books or records relating to any Accounts Receivable (with each location at which chattel paper, if any, is kept being indicated by an "***"):

<u>Grantor</u>	<u>Mailing Address</u>	<u>County</u>	<u>State</u>
King (and all subsidiaries)	501 Fifth Street, Bristol	Sullivan	TN 37620
Parkedale	(post acquisition) 870 Parkedale Road Rochester	Oakland	MI 48307

- (c) Set forth below opposite the name of each Grantor are all the places of business of such Grantor not identified in paragraph (a) or (b) above:

<u>Grantor</u>	<u>Mailing Address</u>	<u>County</u>	<u>State</u>
King	NONE		
Monarch	NONE		
Nevada	NONE		
Parkedale	870 Parkedale Road Rochester	Oakland	MI 48307

- (d) Set forth below opposite the name of each Grantor are all the locations where such Grantor maintains any Collateral not identified above:

<u>Grantor</u>	<u>Mailing Address</u>	<u>County</u>	<u>State</u>
King	NONE		
Monarch	(inventory valued at approximately \$7,202 acquired from Glaxo Wellcome in November 1997 and presently located in a warehouse owned by Cesar Castillo, Inc., at the below address in Puerto Rico) 49 Angel Buonomo Street Tres Monojitas Industrial Park Hato Rey, Puerto Rico 00918		
Nevada	NONE		
Parkedale	(leased inventory warehouse space) 51151 & 51103 Celeste Drive Shelby Township	Macomb	MI 48315

- (e) Set forth below opposite the name of each Grantor are the names and addresses of all persons other than such Grantor that have possession of any of the Collateral of such Grantor:

<u>Grantor</u>	<u>Mailing Address</u>	<u>County</u>	<u>State</u>
King	NONE		
Monarch	NONE		
Nevada	NONE		
Parkedale	NONE*		

3. *Unusual Transactions.* All Accounts Receivable have been originated by the Grantors and all Inventory has been acquired by the Grantors in the ordinary course of business.

Other than existing inventory acquired in conjunction with acquisitions by Monarch of pharmaceutical product lines, and inventory to be acquired pursuant to acquisition of the pharmaceutical product lines from Warner Lambert.

4. *File Search Reports.* Attached hereto as Schedule 4(A) are true copies of file search reports from the Uniform Commercial Code filing offices where filings

*Certain inventory being acquired by Parkedale as part of the Acquisition will be located at Warner-Lambert distribution centers located at 400 W. Lincoln Ave., Lititz, PA, and 1350 Estes Ave., Elk Grove Village, IL until being transferred to Borrower's facility in Bristol, TN within 90 days of the Closing Date.

TRADEMARK

REEL: 1759 FRAME: 0703

described in Section 3.19 of the Credit Agreement are to be made. Attached hereto as Schedule 4(B) is a true copy of each financing statement or other filing identified in such file search reports.

5. *UCC Filings.* Duly signed financing statements on Forms UCC-1 ^{and UCC-3} in substantially the form of Schedule 5 hereto have been prepared for filing in the Uniform Commercial Code filing office in each jurisdiction where a Grantor has Collateral as identified in Section 2 hereof.
6. *Schedule of Filings.* Attached hereto as Schedule 6 is a schedule setting forth, with respect to the filings described in Section 5 above, each filing and the filing office in which such filing is to be made.
7. *Filing Fees.* All filing fees and taxes payable in connection with the filings described in Section 5 above have been paid.
8. *Stock Ownership.* Attached hereto as Schedule 8 is a true and correct list of all the duly authorized, issued and outstanding stock of each Subsidiary and the record and beneficial owners of such stock. Also set forth on Schedule 8 is each equity investment of the Borrower and each Subsidiary that represents 50% or less of the equity of the entity in which such investment was made.
9. *Notes.* Attached hereto as Schedule 9 is a true and correct list of all notes held by the Borrower and each Subsidiary and all intercompany notes between the Borrower and each Subsidiary of the Borrower and between each Subsidiary of the Borrower and each other such Subsidiary.
10. *Advances.* Attached hereto as Schedule 10 is (a) a true and correct list of all advances made by the Borrower to any Subsidiary of the Borrower or made by any Subsidiary of the Borrower to the Borrower or any other Subsidiary of the Borrower, which advances will be on and after the date hereof evidenced by one or more intercompany notes pledged to the Collateral Agent under the Pledge Agreement, and (b) a true and correct list of all unpaid intercompany transfers of goods sold and delivered by or to the Borrower or any Subsidiary of the Borrower.
11. *Mortgage Filings.* Attached hereto as Schedule 11 is a schedule setting forth, with respect to each Mortgaged Property, (i) the exact corporate name of the corporation that owns such property as such name appears in its certificate of incorporation, (ii) if different from the name identified pursuant to clause (i), the exact name of the current record owner of such property reflected in the records of the filing office for such property identified pursuant to the following clause and (iii) the filing office in which a Mortgage with respect to such property must be filed or recorded in order for the Collateral Agent to obtain a perfected security interest therein.

IN WITNESS WHEREOF, the undersigned have duly executed this certificate on this 27th day of February, 1998.

KING PHARMACEUTICALS, INC.

by: Brian G. Shrader, CFO

Name: Brian G. Shrader

Title: Executive Vice President and
Chief Financial Officer

by: John A. Bellamy

Name: John A. A. Bellamy

Title: Executive Vice President and
General Counsel

Schedule 1 to the
Perfection Certificate

Changes in Corporate Structure

None, other than corporate name changes specified in Section 1(b) of the Perfection Certificate.

Schedules 4(A) and 4(B)
On File at Cravath, Swaine & Moore

TRADEMARK
REEL: 1759 FRAME: 0707

Schedule 5
On File at Cravath, Swaine & Moore

SCHEDULE 6

TRADEMARK
REEL: 1759 FRAME: 0709

UCC-1 Financing Statements

<u>Filing</u>	<u>Filing Office</u>
1. King Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Sullivan Co. (Bristol), TN Real Estate Records
2. King Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Tennessee Secretary of State
3. King Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Sullivan Co. (Bristol), TN
4. Monarch Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Tennessee Secretary of State
5. Monarch Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Sullivan Co. (Bristol), TN
6. King Pharmaceuticals of Nevada, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Tennessee Secretary of State
7. King Pharmaceuticals of Nevada, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Sullivan Co., TN

TRADEMARK

REEL: 1759 FRAME: 0710

<u>Filing</u>	<u>Filing Office</u>
8. Parkedale Pharmaceuticals, Inc. (Debtor)	Tennessee Secretary of State
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
9. Parkedale Pharmaceuticals, Inc. (Debtor)	Sullivan Co., TN
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
10. Royal Vet (Debtor)	Sullivan Co. (Bristol), TN
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
11. Royal Vet (Debtor)	Tennessee Secretary of State
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
12. King Pharmaceuticals Animal Health (Debtor)	Tennessee Secretary of State
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
13. King Pharmaceuticals Animal Health (Debtor)	Sullivan Co. (Bristol), TN
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
14. Show Winner (Debtor)	Tennessee Secretary of State
Credit Suisse First Boston, as Collateral Agent (Secured Party)	

<u>Filing</u>	<u>Filing Office</u>
15. Show Winner (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Sullivan Co. (Bristol), TN
16. Parkedale Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Oakland Co., MI (Real Estate)
17. King Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Oakland Co., MI
18. King Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Michigan Secretary of State
19. Parkedale Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Oakland Co., MI
20. Parkedale Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	Michigan Secretary of State
21. King Pharmaceuticals, Inc. (Debtor) Credit Suisse First Boston, as Collateral Agent (Secured Party)	New York Secretary of State

TRADEMARK

REEL: 1759 FRAME: 0712

<u>Filing</u>	<u>Filing Office</u>
22. King Pharmaceuticals, Inc. (Debtor)	New York Co., NY
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
23. King Pharmaceuticals, Inc. (Debtor)	Nevada Secretary of State
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
24. King Pharmaceuticals, Inc. (Debtor)	Clark Co., NV
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
25. King Pharmaceuticals of Nevada, Inc. (Debtor)	Clark Co., NV
Credit Suisse First Boston, as Collateral Agent (Secured Party)	
26. King Pharmaceuticals of Nevada, Inc. (Debtor)	Nevada Secretary of State
Credit Suisse First Boston, as Collateral Agent (Secured Party)	

TRADEMARK

REEL: 1759 FRAME: 0713

Schedule 8 to the
Perfection Certificate

List of All Duly Authorized, Issued and Outstanding Stock of Each Subsidiary and the Record
and Beneficial Owners of Same

<u>Subsidiary</u>	<u>Number of Shares Authorized, Issued and Outstanding</u>	<u>Beneficial Owner</u>
Monarch Pharmaceuticals, Inc.	1,000	King Pharmaceuticals, Inc.
King Pharmaceuticals of Nevada, Inc.	25,000	King Pharmaceuticals, Inc.
Parkedale Pharmaceuticals, Inc.	1,000	King Pharmaceuticals, Inc.

Schedule 9 to the
Perfection Certificate

List of Notes Held by Borrower and Subsidiaries

None

Schedule 10(a) to the
Perfection Certificate

Intercompany Notes

None

Unpaid Intercompany Transfers of Goods Sold

Payable by Monarch Pharmaceuticals, Inc., to King Pharmaceuticals, Inc.:

<u>Description</u>	<u>Invoice #</u>	<u>Due Date</u>	<u>Amount</u>
1. Proctocort Supp., Lot #KA08	9483	2/28/98	\$16,060.96
2. Proctocort Supp., Lot #KA08	9501	3/01/98	\$ 177.60
3. Proctocort Supp., Sample Pks, Lot #KA11	9531	3/08/98	\$31,958.53
4. Nucfed Ped. Ex., Lot #KB7380	9617	3/18/98	\$ 3,434.40
5. Tussend Elixer 16 oz. Lot #KB02	9620	3/18/98	\$ 3,052.48
6. Tussend Elixer 16 oz. Lot #KB03	-----	3/19/98	<u>\$ 3,109.96</u>
TOTAL:			\$57,793.93

Mortgage Filings

Property Address: 501 Fifth Street, Bristol, Sullivan County, Tennessee
Deed Book Reference: Deed Book 343, Page 270
Corporate Name of Owner: King Pharmaceuticals, Inc.
Record Name of Owner: RSR Acquisition Corporation
Filing Office: Registrar of Deeds, Sullivan County Courthouse, Bristol, Tennessee

Property Address: Olive Street, Bristol, Sullivan County, Tennessee
Deed Book Reference: Deed Book 386, Page 674
Corporate Name of Owner: King Pharmaceuticals, Inc.
Record Name of Owner: King Pharmaceuticals, Inc.
Filing Office: Registrar of Deeds, Sullivan County Courthouse, Bristol, Tennessee

Property Address: Olive Street, Bristol, Sullivan County, Tennessee
Deed Book Reference: Deed Book 390, Page 185
Corporate Name of Owner: King Pharmaceuticals, Inc.
Record Name of Owner: King Pharmaceuticals, Inc.
Filing Office: Registrar of Deeds, Sullivan County Courthouse, Bristol, Tennessee

Property Address: 870 Parkdale Road, Rochester, Oakland County, Michigan
Corporate Name of Owner: Parke, Davis & Company
Record Name of Owner: Parke, Davis & Company
Filing Office: Registrar of Deeds Office, Oakland County, Michigan

SUPPLEMENT NO _____ dated as of _____, to the Security Agreement dated as of February 27, 1998, among KING PHARMACEUTICALS, INC., a Tennessee corporation (the "Borrower"), each subsidiary of the Borrower listed on Schedule I thereto (each such subsidiary individually a "Guarantor" and collectively, the "Guarantors"; the Guarantors and the Borrower are referred to collectively herein as the "Grantors") and CREDIT SUISSE FIRST BOSTON, a bank organized under the laws of Switzerland, acting through its New York Branch ("CSFB"), as collateral agent (in such capacity, the "Collateral Agent") for the Secured Parties (as defined herein).

A. Reference is made to (a) the Credit Agreement dated as of February 27, 1998 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Borrower, the lenders from time to time party thereto (the "Lenders"), CSFB, as administrative agent (in such capacity, the "Administrative Agent"), Collateral Agent and swingline lender, and Wachovia Bank, N.A., as issuing bank (in such capacity, the "Issuing Bank"), and (b) the Guarantee Agreement dated as of February 27, 1998 (as amended, supplemented or otherwise modified from time to time, the "Guarantee Agreement"), among the Guarantors and the Collateral Agent.

B. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Security Agreement and the Credit Agreement.

C. The Grantors have entered into the Security Agreement in order to induce the Lenders to make Loans and the Issuing Bank to issue Letters of Credit. Section 7.15 of Security Agreement provides that additional Subsidiaries of the Borrower may become Grantors under the Security Agreement by execution and delivery of an instrument in the form of this Supplement. The undersigned Subsidiary (the "New Grantor") is executing this Supplement in accordance with the requirements of the Credit Agreement to become a Grantor under the Security Agreement in order to induce the Lenders to make additional Loans and the Issuing Bank to issue additional Letters of Credit and as consideration for Loans previously made and Letters of Credit previously issued.

Accordingly, the Collateral Agent and the New Grantor agree as follows:

SECTION 1. In accordance with Section 7.15 of the Security Agreement, the New Grantor by its signature below becomes a Grantor under the Security Agreement with the same force and effect as if originally named therein as a Grantor and the New Grantor hereby (a) agrees to all the terms and provisions of the Security Agreement applicable to it as a Grantor thereunder and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct on and as of the date hereof. In furtherance of the foregoing, the New Grantor, as security for the payment and performance in full of the Obligations (as defined in the Security Agreement), does hereby create and grant to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, their successors and assigns, a security interest in and lien on all of the New Grantor's right, title and interest in and to the Collateral (as defined in the Security Agreement) of the New Grantor. Each reference to a "Grantor" in the Security Agreement shall be deemed to include the New Grantor. The Security Agreement is hereby incorporated herein by reference.

SECTION 2. The New Grantor represents and warrants to the Collateral Agent and the other Secured Parties that this Supplement has been duly authorized, executed and delivered by

TRADEMARK

REEL: 1759 FRAME: 0719

it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms.

SECTION 3. This Supplement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Supplement shall become effective when the Collateral Agent shall have received counterparts of this Supplement that, when taken together, bear the signatures of the New Grantor and the Collateral Agent. Delivery of an executed signature page to this Supplement by facsimile transmission shall be as effective as delivery of a manually signed counterpart of this Supplement.

SECTION 4. The New Grantor hereby represents and warrants that (a) set forth on Schedule I attached hereto is a true and correct schedule of the location of any and all Collateral of the New Grantor and (b) set forth under its signature hereto, is the true and correct location of the chief executive office of the New Grantor.

SECTION 5. Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect.

SECTION 6. THIS SUPPLEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 7. In case any one or more of the provisions contained in this Supplement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and in the Security Agreement shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 8. All communications and notices hereunder shall be in writing and given as provided in Section 7.01 of the Security Agreement. All communications and notices hereunder to the New Grantor shall be given to it at the address set forth under its signature below.

SECTION 9. The New Grantor agrees to reimburse the Collateral Agent for its reasonable out-of-pocket expenses in connection with this Supplement, including the reasonable fees, other charges and disbursements of counsel for the Collateral Agent.

IN WITNESS WHEREOF, the New Grantor and the Collateral Agent have duly executed this Supplement to the Security Agreement as of the day and year first above written.

[Name of New Grantor],

by

Name

Title

Address

CREDIT SUISSE FIRST BOSTON, as
Collateral Agent,

by

Name

Title

by

Name

Title

SCHEDULE I
to Supplement No. ___ to the
Security Agreement

LOCATION OF COLLATERAL

Description

Location